US WorldMeds and Salix announced the launch of Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Lucemyra, a central alpha-2 adrenergic receptor agonist, is the first non-opioid product approved for this indication. It works by binding to receptors on adrenergic neurons thus reducing the release of norepinephrine and decreasing sympathetic tone.
Lucemyra is not indicated as a treatment for opioid use disorder. It should be taken during the period of peak withdrawal symptoms (generally the first 5–7 days after last use of opioid) with dosing guided by symptoms and side effects; total treatment may continue for up to 14 days. Lucemyra should be used as part of a comprehensive management program created by a healthcare provider. Dosage adjustments are recommended for patients with renal or hepatic impairment.
Patients should be advised that Lucemyra may mitigate, but not completely prevent, the symptoms associated with opioid withdrawal. Orthostatic hypotension, bradycardia, dizziness, somnolence, sedation, and dry mouth were among the most commonly reported adverse reactions with Lucemyra use.
“The availability of Lucemyra broadens the range of evidence-based pharmacological options available to healthcare providers, so they can manage the challenges of withdrawal and facilitate their patients’ abrupt discontinuation of opioids,” stated P. Breckinridge Jones, CEO and founder, US WorldMeds.
Lucemyra is available as 0.18mg strength tablets in 36- and 96-count bottles.
For more information call (833) LUCEMYRA or visit Lucemyra.com.
This article originally appeared on MPR